# Jiangsu Recbio Technology Co., Ltd. (Recbio)

> Innovative vaccine company listed on the Hong Kong Stock Exchange (stock code: 02179.HK). Mission: "Protect human health with best-in-class vaccines."

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. is propelled by internally developed technologies. The company has built a comprehensive vaccine innovation engine with three platforms: novel adjuvant, protein engineering, and immunological evaluation. Recbio is one of the few companies capable of independently developing and commercializing a full range of novel adjuvants.

The vaccine portfolio includes more than 10 high-value innovative pipelines covering HPV, shingles, RSV, and other major diseases. Core products recombinant HPV 9-valent vaccine REC603 and novel adjuvanted recombinant shingles vaccine REC610 are under Phase III clinical trials.

**Website:** https://www.recbio.cn  
**Languages:** English (`/en/`), Simplified Chinese (`/cn/`), Traditional Chinese (`/hk/`)

## About Us

- [About Us (English)](https://www.recbio.cn/en/about-us/): Company profile, leadership, milestones, and collaborations
- [About Us (简体中文)](https://www.recbio.cn/cn/about-us/)
- [About Us (繁體中文)](https://www.recbio.cn/hk/about-us/)

### Leadership

| Name | Role |
|------|------|
| Xu Haoyu | Non-executive Director, Chairman of the Board |
| Dr. Liu Yong | Founder, Executive Director and CEO |
| Wang Jing | Executive Director, Chief Quality Officer |
| Wei Qifang | Executive Director, Assistant to the Chairman, and Board Secretary |
| Zhou Yang | Chief Operating Officer |
| Zhou Lei | Finance Director |
| Dr. Hong Kunxue | Chief Science Officer |
| Lan Yong | Executive Director |
| Li Bu | Chief Human Resource Officer |

### Collaborations

Recbio collaborates with leading institutions and industry partners, including:

- China Medical City
- Yangtze River Pharmaceutical Group
- Institute of Biophysics, Chinese Academy of Sciences
- Fudan University
- WuXi Biologics

## Technology Platforms

- [Platforms overview](https://www.recbio.cn/en/platforms/): Vaccine innovation engine
- [Novel adjuvant platform](https://www.recbio.cn/en/platforms/novel-adjuvant/): Independently developed and commercialized novel adjuvants
- [Protein engineering platform](https://www.recbio.cn/en/platforms/protein-engineering/)
- [Immunological evaluation platform](https://www.recbio.cn/en/platforms/immunological-evaluation/)

## Vaccine Pipeline

- [Pipeline overview](https://www.recbio.cn/en/pipeline/pipeline/): Full portfolio of innovative vaccine candidates
- [REC603 — HPV 9-valent vaccine](https://www.recbio.cn/en/pipeline/pipeline/cervical-cancers-genital-warts/rec603/): Recombinant nine-valent HPV vaccine (Hanson's yeast); Phase III clinical trial
- [REC610 — Shingles vaccine](https://www.recbio.cn/en/pipeline/pipeline/shingles/rec610/): Novel adjuvanted recombinant herpes zoster vaccine; Phase III clinical trial in China
- [ReCOV — COVID-19 vaccine](https://www.recbio.cn/en/pipeline/pipeline/covid-19/recov/): Two-component recombinant COVID-19 vaccine

Additional pipeline candidates include REC601, REC602, REC604a, REC604c (HPV), REC608 (herpes simplex), REC609 (CMV), REC617/REC625 (RSV/metapneumovirus), and REC629/REC630 (hepatitis B).

## Investors

- [Investor relations](https://www.recbio.cn/en/investors/): IR hub for listed company (SEHK: 02179.HK)
- [Announcements & circulars](https://www.recbio.cn/en/investors/announcements-circulars/)
- [Financial reports](https://www.recbio.cn/en/investors/financial-reports/)
- [Corporate governance](https://www.recbio.cn/en/investors/corporate-governance/)
- [Prospectus](https://www.recbio.cn/en/investors/prospectus/)
- [Share graph](https://www.recbio.cn/en/investors/share-graph/)
- [Financial calendar](https://www.recbio.cn/en/investors/financial-calendar/)
- [Presentations & webcasts](https://www.recbio.cn/en/investors/presentation-webcast/)
- [Analyst coverage](https://www.recbio.cn/en/investors/analyst-coverage/)

## Media & Careers

- [News & media](https://www.recbio.cn/en/media/): Press releases and company news
- [Careers](https://www.recbio.cn/en/careers/): Job opportunities

## Optional

### Major Business Milestones

**2024**
- License and strategic cooperation with SPIMACO for recombinant HPV-9 vaccine REC603
- Completion of the first batch of subject enrollment in the Phase I clinical trial of the new adjuvant recombinant herpes zoster vaccine in China
- Strategic cooperation agreement with Rongsheng Biotech on the new adjuvant vaccine project
- Initiation of Phase III clinical trial in China of novel adjuvanted recombinant shingles vaccine REC610

**2023**
- Two-component recombinant COVID-19 vaccine ReCOV granted emergency use authorization in Mongolia
- Clinical trial application accepted for novel adjuvanted recombinant shingles vaccine REC610 in China
- Positive interim analysis results for REC610 clinical trial in the Philippines
- Strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre

**2022**
- Philippines approved international multicenter Phase II/III trial of COVID-19 vaccine ReCOV
- Recogen subsidiary launched the world's first lyophilized dosage form mRNA vaccine
- Successfully listed on the main board of the Hong Kong Stock Exchange (SEHK: 2179.HK)
- ReCOV Taizhou production base passed EU QP audit
- Phase II/III trial of ReCOV sequential booster immunization approved in UAE
- Clinical trial approval for ReCOV in the PRC
- Clinical trial approval for mRNA COVID-19 vaccine for Omicron variant in the Philippines
- FDA approval in the Philippines for comparative study between ReCOV and mRNA vaccines
- Clinical trial application accepted for novel adjuvanted recombinant quadrivalent HPV vaccine
- Positive results of multiple overseas Phase II clinical trials of ReCOV
- Completion of first batch of subject enrollment for international multi-center Phase III clinical trial of ReCOV
- Clinical trial approval for REC610 in the Philippines

**2021**
- Completed B+ round and C round of financing
- Launched Phase III clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
- Launched Phase I clinical trial of recombinant COVID-19 vaccine in New Zealand
- Strategic cooperation with Shenzhen Rhegen Biotechnology; established joint venture Wuhan Recogen Biotechnology Co., Ltd. (Recogen) for mRNA vaccine development
- Obtained Drug Production License for COVID-19 vaccine from Jiangsu Food and Drug Administration

**2020**
- Started construction of production facilities for HPV vaccine industrialization
- Completed Series B financing
- Completed Phase I clinical trial of recombinant bivalent HPV16/18 vaccine (Hanson's yeast)
- Completed Phase I clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
- Started COVID-19 vaccine industrialization program

**2019**
- Launched Phase I clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
- Completed Series A financing

**2018**
- Clinical trial approval for recombinant bivalent HPV6/11 vaccine (Hanson's yeast)
- Clinical trial approval for recombinant nine-valent HPV vaccine (Hanson's yeast)

**2017**
- Clinical trial approval for recombinant bivalent HPV16/18 vaccine (Hanson's yeast)

**2016**
- Launched R&D of recombinant herpes zoster vaccine and established adjuvant platform

**2012**
- Established and started operation in Taizhou China Pharmaceutical City Vaccine Engineering Center
- Signed cooperation agreement on HPV preventive vaccine (recombinant Hanson's yeast) with Beijing ABZYMO

**2011**
- Beijing ABZYMO Biosciences Co., Ltd. (the first operating entity) was established

- [Full sitemap](https://www.recbio.cn/sitemap.xml): Complete list of indexable pages